Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 22.58 AUD 1.71% Market Closed
Market Cap: 7.6B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note
TLX
/
Income Statement
/
EPS (Diluted)

Telix Pharmaceuticals Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Telix Pharmaceuticals Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Telix Pharmaceuticals Ltd
ASX:TLX
EPS (Diluted)
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
EPS (Diluted)
AU$0
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
10%
Mesoblast Ltd
ASX:MSB
EPS (Diluted)
$0
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
EPS (Diluted)
$5
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
7%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
EPS (Diluted)
AU$0
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
EPS (Diluted)
AU$0
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Market Cap
7.5B AUD
Industry
Biotechnology

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 158 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The firm's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.

TLX Intrinsic Value
16.35 AUD
Overvaluation 28%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Telix Pharmaceuticals Ltd's EPS (Diluted)?
EPS (Diluted)
0 AUD

Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's EPS (Diluted) amounts to 0 AUD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.